{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:40:30Z","timestamp":1793400030562,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bacterial vaginosis (BV) is one of the common vaginal infections among childbearing women. The usual treatment for BV is metronidazole; hence 30% of women have recurrence within 60 to 90\u2009days after treatment. There are some studies which assessed the effect of secnidazole on BV. The aim of this systematic review was to investigate the effectiveness of secnidazole for treatment of BV.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Cochrane Library, MEDLINE (PubMed), Scopus, and Web of Science (all databases from inception till October 28, 2018) were searched. Primary outcomes were clinical cure rate and microbiologic cure rate and the secondary outcomes were adverse events. Data was extracted from eligible studies by two review authors individually and analyzed by RevMan 5.3.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our search found six trials involving 1528 participants. Treatment with 2\u2009g secnidazole could significantly reduce the risk of BV in patients with three or less episodes of BV in the last year by OR: 7.54 (95% CI, 3.89\u201314.60, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001) and in patients with four or more episodes of BV in the last year (OR: 4.74, 95% CI: 1.51\u201314.84, <jats:italic>p<\/jats:italic>\u2009=\u20090.0.008). Secnidazole (2\u2009g) could significantly increase the microbiologic cure rate in women with 3 or less episodes of BV in the last year (OR: 7.63, 95% CI: 2.30\u201325.33, <jats:italic>p<\/jats:italic>\u2009=\u20090.0009) but not in the women with 4 or more episodes of BV in the last year (OR: 20.17, 95% CI: 1.06\u2013382.45, <jats:italic>p<\/jats:italic>\u2009=\u20090.05). The clinical cure rate, microbiological effect and the therapeutic cure rate of 2\u2009g secnidazole was significantly more than that of 1\u2009g secnidazole.<\/jats:p>\n                <jats:p>The results showed that the clinical cure rate of 2\u2009g secnidazole was not different from the following medications: metronidazole (500\u2009mg bid for 5\u2009days), secnidazole plus vaginal metronidazole, 2\u2009g single dose of oral metronidazole and 2\u2009g secnidazole plus vaginal ornidazole.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This review showed that 2\u2009g and 1\u2009g secnidazole were better than placebo, however, 2\u2009g secnidazole was more effective than 1\u2009g. Secnidazole 2\u2009g was not different from metronidazole (500\u2009mg bid for 5\u2009days), or from secnidazole plus vaginal metronidazole, or 2\u2009g single dose of oral metronidazole or from 2\u2009g secnidazole plus vaginal ornidazole.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-019-0822-2","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T12:49:47Z","timestamp":1571662187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Secnidazole for treatment of bacterial vaginosis: a systematic review"],"prefix":"10.1186","volume":"19","author":[{"given":"Mohamed A.","family":"Abd El Aziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foruzan","family":"Sharifipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6980-0693","authenticated-orcid":false,"given":"Parvin","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayesteh","family":"Jahanfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Marie","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"822_CR1","unstructured":"Gibbs RS, Karlah BY, Haney AF, Nygaard IE. Danforth\u2019s Obstetrics and Gynecology .10th edi. 2008 Lippincott Williams and Wilkins. Philadelphia. PA19106 USA:p.625\u2013640."},{"issue":"1","key":"822_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pop.2008.10.002","volume":"36","author":"Wendy S. Biggs","year":"2009","unstructured":"Biggs WS, Williams RM. Common gynecologic infections. Prim Care 2009;36(1):33\u201351, viii. doi: \n                    https:\/\/doi.org\/10.1016\/j.pop.2008.10.002\n                    \n                  .","journal-title":"Primary Care: Clinics in Office Practice"},{"issue":"6","key":"822_CR3","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/j.1365-2672.2012.05429.x","volume":"113","author":"M Terraf","year":"2012","unstructured":"Terraf M, Tom\u00e1s J. Nader - Mac\u00edas M, Silva C. screening of biofilm formation by beneficial vaginal lactobacilli and influence of culture media components. J Appl Microbiol. 2012;113(6):1517\u201329.","journal-title":"J Appl Microbiol"},{"issue":"11","key":"822_CR4","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/OLQ.0b013e318074e565","volume":"34","author":"EH Koumans","year":"2007","unstructured":"Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, et al. The prevalence of bacterial vaginosis in the United States association with symptoms sexual behaviors and reproductive health. Sex Transm Dis. 2007;34(11):864\u20139.","journal-title":"Sex Transm Dis"},{"key":"822_CR5","doi-asserted-by":"publisher","unstructured":"Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women,\u201d Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006055. doi: \n                    https:\/\/doi.org\/10.1002\/14651858\n                    \n                  . CD006055.pub2.","DOI":"10.1002\/14651858"},{"issue":"8","key":"822_CR6","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/jog.12704","volume":"41","author":"XD Li","year":"2015","unstructured":"Li XD, Tong F, Zhang XJ, Pan WJ, Chen ML, Wang CC, Li X, et al. Incidence and risk factors of bacterial vaginosis among pregnant women: a prospective study in Maanshan city, Anhui Province, China. J Obstet Gynaecol Res. 2015 Aug;41(8):1214\u201322. \n                    https:\/\/doi.org\/10.1111\/jog.12704\n                    \n                  .","journal-title":"J Obstet Gynaecol Res"},{"key":"822_CR7","doi-asserted-by":"crossref","unstructured":"Armstrong NR , Wilson JD. Tinidazole in the treatment of bacterial vaginosis. Int J Womens Health 2009 Agust;1(9):59\u201365.","DOI":"10.2147\/IJWH.S4455"},{"key":"822_CR8","unstructured":"Bacterial vaginosis - CDC fact sheet. (2017, February 16). Retrieved from \n                    https:\/\/www.cdc.gov\/std\/bv\/stdfact-bacterial-vaginosis.htm\n                    \n                  . Accessed 16 Feb 2017."},{"issue":"5","key":"822_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1086\/596632","volume":"199","author":"JM Marrazzo","year":"2009","unstructured":"Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis. 2009;199(5):680\u20133.","journal-title":"J Infect Dis"},{"issue":"Supp l","key":"822_CR10","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1093\/infdis\/jiw159","volume":"214","author":"CS Bradshaw","year":"2016","unstructured":"Bradshaw CS, Sobel JD. Current treatment of bacterial vaginosis - limitations and need for innovation. J Infect Dis. 2016;214(Supp l):S14\u201320.","journal-title":"J Infect Dis"},{"key":"822_CR11","first-page":"1","volume":"64","author":"CDC","year":"2015","unstructured":"CDC. Sexually transmitted disease treatment guidelines. MMWR. 2015;64:1\u2013137.","journal-title":"MMWR"},{"key":"822_CR12","unstructured":"Sobel JD, ed. Bacterial Vaginosis. Waltham, MA: UptoDate 2013. Available at: \n                    www.uptodate.com\/contents\/bacterialvaginosis?topicKey=OBGYN%2F5451&elap\n                    \n                   Accessed 6 April 2017."},{"key":"822_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/705692","volume":"2010","author":"Jean-Marc Bohbot","year":"2010","unstructured":"Bohbot JM, Vicaut E, Fagnen D, Brauman M. Treatment of Bacterial Vaginosis: A Multicenter, Double-Blind, Double-Dummy, Randomised Phase III Study Comparing Secnidazole and Metronidazole. Infect Dis Obstet Gynecol. Volume 2010, Article ID 705692, 6 pages. \n                    https:\/\/doi.org\/10.1155\/2010\/705692","journal-title":"Infectious Diseases in Obstetrics and Gynecology"},{"key":"822_CR14","unstructured":"Videau D, Niel G, Siboulet A, Catalan F. Secnidazole. A 5-nitroimidazole derivative with a long half-life. Br J Vener Dis 1978;54:77\u201380."},{"key":"822_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/OGX.0b013e3181e09621","volume":"65","author":"G Donders","year":"2010","unstructured":"Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet Gynecol Surv. 2010;65:462\u201373.","journal-title":"Obstet Gynecol Surv"},{"key":"822_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ijgo.2004.11.028","volume":"88","author":"JT N\u00fa\u00f1ez","year":"2005","unstructured":"N\u00fa\u00f1ez JT, G\u00f3mez G. Low-dose secnidazole in the treatment of bacterial vaginosis. Int J Gynaecol Obstet. 2005;88:281\u20135.","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"822_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/AOG.0000000000002135","volume":"130","author":"S Hillier","year":"2017","unstructured":"Hillier S, Nyirjesy P, Waldbaum A, Schwebke J, Morgan F, Adetoro N, Braun C. Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial. Obstet Gynecol. 2017;130(2):379.","journal-title":"Obstet Gynecol"},{"issue":"jul21 1","key":"822_CR18","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A. Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ online 2009;339 b2700.","journal-title":"BMJ"},{"key":"822_CR19","unstructured":"Higgins, J., D. Altman, et al.. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. J. Higgins and S. Green, Version 5.1.0 (updated 2011). The Cochrane Collaboration 2011."},{"issue":"6","key":"822_CR20","doi-asserted-by":"publisher","first-page":"678.e1-678.e9","DOI":"10.1016\/j.ajog.2017.08.017","volume":"217","author":"Jane R. Schwebke","year":"2017","unstructured":"Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017, 217;(6):678.e1\u20139. \n                    https:\/\/doi.org\/10.1016\/j.ajog.2017.08.017\n                    \n                  .","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"2","key":"822_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4103\/0253-7613.93859","volume":"44","author":"J Thulkar","year":"2012","unstructured":"Thulkar J, Kriplani A, Agarwal N. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J Pharmacol. 2012 Mar-Apr;44(2):243\u20135. \n                    https:\/\/doi.org\/10.4103\/0253-7613.93859\n                    \n                  .","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"822_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0020-7292(98)00029-0","volume":"62","author":"F Sara\u00e7o\u011flu","year":"1998","unstructured":"Sara\u00e7o\u011flu F, G\u00f6l K, Sahin I, T\u00fcrkkani B, Atalay C, Oztop\u00e7u C. Treatment of bacterial vaginosis with oral or vaginal ornidazole, secnidazole and metronidazole. Int J Gynaecol Obstet. 1998;62(1):59\u201361.","journal-title":"Int J Gynaecol Obstet"},{"issue":"31","key":"822_CR23","first-page":"2201","volume":"88","author":"FM Wang","year":"2008","unstructured":"Wang FM, Qian XD, Xu H, Yu HY. Efficacy of 5-nitroimidazole derivatives in treatment of bacterial vaginosis. Zhonghua Yi Xue Za Zhi. 2008 Aug 12;88(31):2201\u20133.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"11","key":"822_CR24","first-page":"686","volume":"27","author":"N Tariq","year":"2017","unstructured":"Tariq N, Basharat A, Khan DH, Fahim A, Khan MH. Treatment for Symptomatic Bacterial Vaginosis: ARandomized Controlled Trial. J Coll Physicians Surg Pak. 2017;27(11):686\u20139 2743.","journal-title":"J Coll Physicians Surg Pak"},{"key":"822_CR25","unstructured":"401. Nct. A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis. 2015. \n                    Https:\/\/clinicaltrials.gov\/show\/nct02418845\n                    \n                  . Accessed 30 Mar 2016."},{"issue":"4","key":"822_CR26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1089\/jwh.2017.6500","volume":"27","author":"SE Chavoustie","year":"2018","unstructured":"Chavoustie SE, Gersten JK, Samuel MJ, Schwebke JR. A phase 3, multicenter, prospective, open-label study to evaluate the safety of a single dose of Secnidazole 2\u2009g for the treatment of women and Postmenarchal adolescent girls with bacterial Vaginosis. J Women\u2019s Health (Larchmt). 2018 Apr;27(4):492\u20137. \n                    https:\/\/doi.org\/10.1089\/jwh.2017.6500\n                    \n                  .","journal-title":"J Women\u2019s Health (Larchmt)"},{"key":"822_CR27","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ajog.2006.08.016","volume":"195","author":"JE Tolosa","year":"2006","unstructured":"Tolosa JE, Chaithongwongwatthana S, Daly S, et al. The International Infections in Pregnancy (IIP) study: variations in the prevalence of bacterial vaginosis and distribution of morphotypes in vaginal smears among pregnant women. Am J Obstet Gynecol. 2006;195:1198.","journal-title":"Am J Obstet Gynecol"},{"key":"822_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/01.AOG.0000139512.37582.17","volume":"104","author":"RB Ness","year":"2004","unstructured":"Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004;104:761.","journal-title":"Obstet Gynecol"},{"key":"822_CR29","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1086\/462427","volume":"192","author":"L Myer","year":"2005","unstructured":"Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in south African women: a nested case-control study. J Infect Dis. 2005;192:1372.","journal-title":"J Infect Dis"},{"key":"822_CR30","volume":"10","author":"J Amaya-Guio","year":"2016","unstructured":"Amaya-Guio J, Viveros-Carreno DA, Sierra-Barrios EM, Martinez-Velasquez MY, Grillo-Ardila CF. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev. 2016;10:CD011701.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"822_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2217\/fmb-2017-0270","volume":"13","author":"Paul Nyirjesy","year":"2018","unstructured":"Nyirjesy P, Schwebke JR. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol. 2018:13(5). \n                    https:\/\/doi.org\/10.2217\/fmb-2017-0270\n                    \n                  .","journal-title":"Future Microbiology"},{"key":"822_CR32","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases, 8th Edi","author":"JL Nagel","year":"2015","unstructured":"Nagel JL, Aronoff DM. Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases, 8th Edi; 2015."},{"key":"822_CR33","unstructured":"SOLOSEC (secnidazole) oral granules Initial U.S. Approval: 2017: \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209363s000lbl.pdf\n                    \n                  . 2017."},{"key":"822_CR34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/0002-9378(88)90078-6","volume":"158","author":"DA Eschenbach","year":"1988","unstructured":"Eschenbach DA, Hillier S, Critchlow C, et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol. 1988;158:819.","journal-title":"Am J Obstet Gynecol"},{"key":"822_CR35","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa043802","volume":"353","author":"DN Fredricks","year":"2005","unstructured":"Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353:1899.","journal-title":"N Engl J Med"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-019-0822-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12905-019-0822-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-019-0822-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T23:06:13Z","timestamp":1603148773000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-019-0822-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1186\/s12905-019-0822-2","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N\/A","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Parvin Abedi and Shayesteh Jahanfar are both associate editors of BMC Pregnancy and Childbirth and other than this, the authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}